EXOSC7: A Protein Implicated in Multiple Diseases (G23016)

Target Name: EXOSC7

NCBI ID: G23016

EXOSC7

EXOSC7: A Protein Implicated in Multiple Diseases

EXOSC7 (EXOSC7 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell signaling, and its dysfunction has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and cardiomyopathy. As a drug target or biomarker, EXOSC7 is of great interest to researchers because it provides a potential target for new therapies.

The EXOSC7 protein is composed of 194 amino acids and has a molecular weight of 21 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is involved in the regulation of cell signaling pathways. The protein has four known isoforms, which are different forms of the protein that are produced by alternative splicing of the gene.

One of the key functions of EXOSC7 is its role in regulating neurotransmitter release from nerve terminals. This is important for the function of the nervous system, as neurotransmitters are responsible for transmitting signals between neurons and other cells. EXOSC7 is known to play a key role in the regulation of the release of dopamine, a neurotransmitter that is involved in mood, emotion, and motivation.

EXOSC7 is also involved in the regulation of cell signaling pathways that are important for many different cellular processes, including cell growth, apoptosis (programmed cell death), and inflammation. Its role in these processes is thought to be related to its ability to regulate the formation of stress granules, which are structures that are involved in the regulation of cellular signaling.

In addition to its role in cell signaling, EXOSC7 is also of interest as a potential drug target or biomarker because of its involvement in the regulation of cellular processes that are important for many diseases. For example, EXOSC7 has been implicated in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Its role in these processes may make it an attractive target for new therapies.

EXOSC7 is also of interest as a potential biomarker for cancer, as its dysfunction has been implicated in the development and progression of many types of cancer. For example, EXOSC7 has been shown to be downregulated in many types of cancer, including breast, ovarian, and prostate cancers. This suggests that these cancers may be sensitive to drugs that target EXOSC7.

EXOSC7 is also of interest as a potential drug target for treating cardiomyopathy, a condition in which the heart muscle becomes weakened or damaged and is not able to pump enough blood to the body. The dysfunction caused by cardiomyopathy can be irreversible, and is often associated with serious complications, including heart failure and sudden cardiac death. EXOSC7 has been shown to play a key role in the regulation of cardiac function, and its dysfunction may be contributing to the development and progression of cardiomyopathy.

In conclusion, EXOSC7 is a protein that is expressed in various tissues of the body and is involved in the regulation of cell signaling pathways. Its dysfunction has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and cardiomyopathy. As a drug target or biomarker, EXOSC7 is of great interest to researchers because it provides a potential target for new therapies. Further research is needed to fully understand its role in these processes and its potential as a drug target or biomarker.

Protein Name: Exosome Component 7

Functions: Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes

The "EXOSC7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EXOSC7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets